GlobeNewswire Inc.··NaMolecular Partners Posts $61.7M Loss but Funds Pipeline Through 2028
Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.
MOLNfinancial resultsclinical trial